Crispr Therapeutics AG (NASDAQ:CRSP) has been given an average recommendation of “Hold” by the fifteen analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $49.88.
Several research firms have issued reports on CRSP. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target (down previously from $15.00) on shares of Nabriva Therapeutics in a research note on Wednesday, May 1st. Evercore ISI began coverage on Homology Medicines in a research note on Thursday, April 11th. They issued an “outperform” rating and a $29.00 price target on the stock. BTIG Research lifted their price target on Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, April 22nd. Zacks Investment Research downgraded EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Chardan Capital set a $73.00 price target on Crispr Therapeutics and gave the company a “buy” rating in a research note on Friday, June 7th.
In other news, President Rodger Novak sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $50.00, for a total value of $2,500,000.00. Following the completion of the transaction, the president now owns 848,007 shares in the company, valued at approximately $42,400,350. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $42.03, for a total value of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares of the company’s stock, valued at approximately $7,840,360.26. The disclosure for this sale can be found here. Insiders sold a total of 160,000 shares of company stock valued at $7,511,000 in the last 90 days. 21.40% of the stock is owned by corporate insiders.
Shares of CRSP traded down $0.07 during midday trading on Monday, hitting $49.11. The stock had a trading volume of 287,431 shares, compared to its average volume of 566,607. The firm has a 50 day moving average of $43.23. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $66.26. The firm has a market capitalization of $2.60 billion, a price-to-earnings ratio of -14.28 and a beta of 3.11. The company has a current ratio of 15.84, a quick ratio of 15.84 and a debt-to-equity ratio of 0.08.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $1.50 million. During the same period in the prior year, the business earned ($0.62) EPS. The business’s revenue for the quarter was down 78.6% compared to the same quarter last year. On average, sell-side analysts predict that Crispr Therapeutics will post -3.82 earnings per share for the current fiscal year.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Book Value Per Share – BVPS
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.